Working… Menu

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03907527
Recruitment Status : Recruiting
First Posted : April 9, 2019
Last Update Posted : January 11, 2021
National Cancer Institute (NCI)
Precigen, Inc
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 1, 2022
Estimated Study Completion Date : April 1, 2026